In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
SAN DIEGO, CA / ACCESS Newswire / January 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all investors ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...